Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582073 · ClinicalTrials.gov registry record · Phase 2
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
A Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
- 1
- Study location
NCT02582073 is a Phase 2 study of Seasonal Allergic Rhinitis that has completed, run by Allergy Therapeutics. The registered enrollment target is 265 participants, below the 652-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02582073, a Phase 2 study of Seasonal Allergic Rhinitis, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
- 1
- Study location
Study Summary
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. The current therapeutic dose regimen for Grass MATA MPL is a course of four injections of 300, 800, 2000 and 2000 SU (Standardized Units), administered at weekly intervals (cumulative dose 5100 SU). Two new cumulative doses of the Grass MATA MPL 10200 SU and 18200 SU are being developed to compare with the current dose. The study is designed to explore the benefit/risk of increasing the cumulative allergen dose of the Grass MATA MPL immunotherapy comparing these doses with the current dose of Grass MATA MPL, Grass MATA (without MPL) and placebo.
Conditions Studied
Interventions
- BIOLOGICAL Placebo (0.5ml)
- BIOLOGICAL Placebo (1.0ml)
- BIOLOGICAL Grass MATA MPL (0.5ml) 5100SU
- BIOLOGICAL Grass MATA MPL (1.0ml) 10200SU
- BIOLOGICAL Grass MATA MPL (1.0ml) 18200SU
Study Locations (1)
New Jersey
- Inflamax Research Inc. - Neptune City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2015-11-07 |
| Est. Completion | 2017-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582073
The ClinicalTrials.gov registry entry for NCT02582073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 652-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (59% lower). The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 5 interventions - of which Placebo (0.5ml) is the first listed.
NCT02582073 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02582073 about?
NCT02582073 is a clinical study titled "Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™". There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. The current therape...
What is the current status of trial NCT02582073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2015-11-07. Estimated completion is 2017-04-28.
What conditions does trial NCT02582073 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT02582073?
The interventions under investigation include: Placebo (0.5ml) (BIOLOGICAL), Placebo (1.0ml) (BIOLOGICAL), Grass MATA MPL (0.5ml) 5100SU (BIOLOGICAL), Grass MATA MPL (1.0ml) 10200SU (BIOLOGICAL), Grass MATA MPL (1.0ml) 18200SU (BIOLOGICAL).
Who is sponsoring clinical trial NCT02582073?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02582073 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
COMPLETED · Phase 2
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.